Overview
Every week, safety scientists at pharmaceutical organizations process hundreds of Individual Case Safety Reports (ICSRs) under 15-day regulatory deadlines. Each report may arrive in a different language, reference local trade names, follow a different format, and be subject to a different regulatory jurisdiction. Despite this complexity, the core decision is always the same: does this case contain a safety signal worth escalating?
The agent factory in pharma is changing how this complexity is handled. Instead of scaling teams linearly, organizations are now scaling intelligence through orchestrated AI systems that manage volume, variability, and decision-making in parallel.
For decades, pharmacovigilance workflows have been manual and sequential. However, that constraint is now being systematically removed. This shift is not about replacing scientists; rather, it is about ensuring their expertise is applied where it truly matters.
Why Agent Factory in Pharma Is a Necessary Evolution
A traditional machine learning pipeline is fixed and sequential, that is, data enters one end, and a prediction comes out the other. It answers one question per invocation and cannot reason, delegate, or self-evaluate.
An agent factory is fundamentally different. It is a software system that dynamically instantiates, configures, coordinates, and retires specialized AI agents, each focused on a distinct task, without constant human direction. Think of it as a smart production floor where agents reason over inputs, call external tools (databases, regulatory APIs, medical ontologies), evaluate their own output quality, and hand off tasks with structured context rather than raw data. The specific agents that form the ICSR processing stack are described in detail in the Architecture section below.
In pharmacovigilance, this distinction matters because processing a single adverse event report is not one task, it includes language detection, translation verification, entity extraction, MedDRA coding, duplicate detection, seriousness classification, causality assessment, and listedness determination. These tasks have dependencies, but many can run in parallel. An agent factory handles that concurrency with structured handoffs while maintaining a complete audit trail.
Architecture: How a Pharma Agent Factory Is Built
At the center of the architecture sits an Orchestrator Agent. It receives inbound cases, sequences specialized agents in the optimal order, monitors confidence scores against defined thresholds, tracks SLA timers, and makes the routing decision: auto-submit or escalate to a human reviewer. The human side of that routing decision, who reviews, under what conditions, and how overrides are recorded, is described in The Human-AI Collaboration Model.
Each specialized agent wraps a large language model with a targeted system prompt, a curated set of tools, and a strict output schema, typically JSON, carrying the medical coding, confidence score, and provenance chain. This structured contract ensures agents can communicate reliably without ambiguity.
A representative agent stack for ICSR processing includes:
- Ingestion & Language Agent: Detects language, normalizes format, applies source metadata
- Translation & Verification Agent: Produces a target-language version and back-translates to validate fidelity
- Entity Extraction Agent: Identifies drug names, adverse events, patient demographics, and reporter details
- MedDRA Coding Agent: Maps extracted events to standardized MedDRA preferred terms and system organ classes
- Seriousness & Listedness Agent: Classifies against ICH E2A criteria and company core data sheets
- Duplicate Detection Agent: Queries historical case databases using semantic similarity, not just field matching
- Orchestrator: Aggregates confidence signals and routes the case
These same agents, with their real-world timing, are traced through a Japanese hospital case in the triage walkthrough below.
Shared Memory: The Audit Foundation
Pharmacovigilance cases are not point-in-time events. They evolve over weeks through follow-up queries, sponsor communications, and regulatory responses. A shared, append-only vector database stores every agent decision timestamped, agent-attributed, and cryptographically hashed at ingestion. This serves two purposes: it gives inspectors a queryable, machine-generated audit trail that exceeds what any manual process produces, and it enables agents to retrieve semantically similar historical cases for calibration when coding ambiguous events.
This shared memory layer is the foundation on which the four-layer compliance architecture is built. Without it, the per-agent decision layer described there would have no persistent store to write to.
Autonomous Adverse Event Triage: A Worked Example
Consider a serious adverse event report arriving from a hospital in Japan. It is written in Japanese, uses a local trade name for the drug, and references informal clinical language. In a traditional workflow, this report enters a queue, waits for a bilingual safety scientist, and is processed sequentially over hours.
In an agent factory, using the stack introduced in the Architecture section, the following runs in parallel:
- Ingestion & Language Detection (~0.3 seconds): Source metadata captured, Japanese confirmed
- Translation & Back-Verification (~4 seconds): Translated to English, back-translated for fidelity check
- Entity Extraction & MedDRA Coding (~6 seconds): Trade name resolved to INN, adverse event mapped to preferred term
- Seriousness & Listedness Classification (~3 seconds): ICH E2A criteria applied, company label queried
- Duplicate Detection (~5 seconds): Semantic search across the existing case database
Total elapsed time: under 20 seconds. The Orchestrator then scores the case. High-confidence output routes directly to the regulatory gateway; low-confidence output escalates with the full decision trail attached, so the reviewing scientist sees not a raw report but a structured dossier explaining exactly where the system was uncertain and why.
In a 2024 pilot, Roche achieved 91% MedDRA coding accuracy at under 30 seconds per case, with only 8% of cases requiring human review. Across early enterprise deployments, organizations have reported a 92% reduction in ICSR processing time, a 15× increase in throughput, and a sub-5% escalation rate operating continuously across time zones without the shift constraints that govern human teams. The implementation patterns that made Roche’s deployment successful are examined in the Implementation section.
Signal Detection: From Data Tables to Synthesized Dossiers
Beyond individual reports, agent factories excel at pattern recognition across thousands of ICSRs. Traditional disproportionality methods (PRR, ROR, BCPNN) produce tables that still require human interpretation. Agent factories go further by orchestrating:
- Statistical Trigger Agent: Runs calculations and flags combinations crossing thresholds.
- Literature Surveillance Agent: Monitors PubMed, Embase, and pre-prints.
- Biological Plausibility Agent: Queries mechanism-of-action databases.
- Benefit-Risk Synthesis Agent: Produces ICH E2C(R2)-compliant narratives.
- Regulatory Action Agent: Assesses label update or REMS needs.
By the time a signal reaches a pharmacovigilance physician, it arrives as a synthesized dossier—ready for expert judgment instead of manual preparation.
Expanding Upstream: Agent Factories in Clinical Development
The same architecture applies throughout the clinical development lifecycle, where the cost of delay is measured in years and billions. Clinical development averages 10–15 years and more than $2.6 billion per approved drug (DiMasi et al., Tufts CSDD). The Orchestrator-and-specialist-agent model described in the Architecture section maps directly onto the operational bottlenecks below:
One capability that becomes possible at scale but is impractical manually is network-wide EHR screening across multiple investigational sites simultaneously, identifying eligible patients from structured records before a site coordinator manually reviews a single chart. This changes recruitment from a site-by-site funnel into a parallel discovery process, applying the same parallel agent execution model seen in the 20-second ICSR triage example to patient matching across dozens of sites at once.
Both pharmacovigilance and clinical development deployments share the same compliance requirements. Whether processing an ICSR or assembling a CTD module, the auditability obligations are identical, as explained in the following section.
Compliance Architecture: Auditability as a Design Requirement
In regulated pharmaceutical environments, an AI system that cannot be audited is a system that cannot be used. Agent factories in pharma treat auditability as a first-class architectural requirement, not a post-hoc feature. The Shared Memory layer described in the Architecture section is what makes this four-layer model persistent and queryable.
A compliant implementation maintains four explicit layers:
- Immutable raw input layer: Source documents stored with cryptographic hashes, timestamped at receipt
- Per-agent decision layer: Inputs, system prompts, model version, output, and confidence score recorded for every agent invocation; this is the layer that captures MedDRA coding decisions made during triage and signal synthesis decisions made during aggregate analysis.
- Orchestrator routing layer: Decision logic, threshold values, and escalation rationale captured; corresponds directly to the routing step described at the end of the triage walkthrough.
- Final output and human override layer: Submission package linked to full decision trail; any human correction recorded with rationale; this layer is what the Human-AI Collaboration Model writes to when a reviewer overrides an agent decision.
This structure satisfies FDA 21 CFR Part 11 (electronic records), EMA GxP requirements, and ICH E6(R3) data integrity standards. It enables a regulator to replay the complete decision path for any submission—something that manual processes, which rely on email threads and handwritten notes, cannot provide.
The Human-AI Collaboration Model
Agent factories in pharma do not remove humans from pharmacovigilance, they change the threshold at which human judgment is required. This section defines exactly where that threshold sits and how it is maintained, completing the picture of the routing decision introduced in the Architecture section.
Routine, well-defined tasks are production-ready for autonomous execution: MedDRA coding of common events, duplicate detection, timeline classification, translation verification, and structured report generation. A recent 2024 pilot reported high coding accuracy (~90%) with limited escalation (~8%), reinforcing the feasibility of this approach. The specific tasks that ran autonomously in that pilot map directly to the agent stack and triage flow described earlier.
Expert human review remains essential for a defined set of decisions: novel or unexpected safety signals, complex benefit-risk judgments, trial halt recommendations, drug withdrawal considerations, and any case where the Orchestrator’s confidence falls below the escalation threshold. These are the cases where years of clinical experience genuinely matter and where scientists should be spending their time. For signal detection cases, the synthesized dossier produced by the five-agent signal detection ensemble is what the reviewing physician receives.
When a human reviewer overrides an agent decision, that override is logged at Layer 4 of the compliance architecture, attributed to the reviewer, and fed back into the calibration pipeline. Human corrections become a training signal, not just one-off fixes.
Implementation: What Early Adopters Have Learned
Organizations that have deployed agent factories in pharmacovigilance share several patterns that distinguish successful implementations from stalled ones. Roche’s 2024 pilot, 91% MedDRA coding accuracy, under 30 seconds per case, 8% human review, is the reference deployment against which these patterns are grounded.
Start at the boundary, not the core. Roche began with lower-risk tasks like intake normalization, language detection, and translation before extending to coding and classification. This approach builds organizational trust and generates labeled data for model calibration before touching causality or the signal detection ensemble.
Design every autonomous path with a manual fallback. Regulators expect systems to degrade gracefully under failure conditions. Every agent handoff should have a defined fallback behavior, and every escalation path should route to a human with the full decision context attached — consistent with the four-layer compliance architecture that captures those fallback events in the Orchestrator routing layer.
Treat confidence scores as a first-class metric. The escalation threshold that determines when a case reaches a human reviewer is not a default setting, it is a calibrated parameter that should be tuned against your case mix, regulatory jurisdiction, and product portfolio. Uncalibrated confidence scores produce either unsafe automation (too permissive) or useless escalation rates (too conservative).
Validate against regulatory expectations from day one. Aligning with FDA Computer Software Assurance (CSA) guidance and ICH Q10 quality system requirements at the design stage is far less costly than retroactive validation. The compliance architecture described earlier was designed with these requirements in mind from the outset—not retrofitted after deployment.
Future of Agent Factory in Pharma: From Reactive to Predictive Safety
The current deployment of agent factories is primarily reactive: reports arrive, the triage pipeline processes them, and the signal detection ensemble surfaces patterns after accumulation. The next evolution moves upstream by detecting signals before they accumulate.
Agent factory in pharma begins to ingest real-world evidence streams such as insurance claims, EHR data, wearable signals, and social health platforms alongside pre-print literature and genomic databases, to surface potential safety signals before they manifest in sufficient ICSR volume to trigger statistical detection. This shifts pharmacovigilance from a reporting function to a predictive surveillance function. The same Orchestrator-and-specialist-agent architecture described throughout this post applies; only the data sources and the temporal horizon change.
Regulatory agencies are responding. The FDA’s AI/ML action plan and the EMA’s 2023 reflection paper on AI in medicines development both signal that frameworks for predictive pharmacovigilance are being actively developed.
Conclusion
A production-grade agent factory in pharma is modular, auditable, confidence-calibrated, and built for graceful degradation. It doesn’t eliminate human expertise, however, it amplifies it by removing mechanical drudgery. For pharma organizations facing growing ICSR volumes and tightening global deadlines, the technology exists today. The real question is how quickly and how well you build it.
Author’s Note: This article was supported by AI-based research and writing, with Claude 4.6 assisting in the creation of text and images.
